Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

DOI Web Site 2 Citations
  • Young-Jun Park
    Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Dora Pinto
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Alexandra C. Walls
    Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Zhuoming Liu
    Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
  • Anna De Marco
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Fabio Benigni
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Fabrizia Zatta
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Chiara Silacci-Fregni
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Jessica Bassi
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Kaitlin R. Sprouse
    Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Amin Addetia
    Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • John E. Bowen
    Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Cameron Stewart
    Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Martina Giurdanella
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Christian Saliba
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Barbara Guarino
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Michael A. Schmid
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Nicholas M. Franko
    Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
  • Jennifer K. Logue
    Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
  • Ha V. Dang
    Vir Biotechnology, San Francisco, CA, USA.
  • Kevin Hauser
    Vir Biotechnology, San Francisco, CA, USA.
  • Julia di Iulio
    Vir Biotechnology, San Francisco, CA, USA.
  • William Rivera
    Vir Biotechnology, San Francisco, CA, USA.
  • Gretja Schnell
    Vir Biotechnology, San Francisco, CA, USA.
  • Anushka Rajesh
    Vir Biotechnology, San Francisco, CA, USA.
  • Jiayi Zhou
    Vir Biotechnology, San Francisco, CA, USA.
  • Nisar Farhat
    Vir Biotechnology, San Francisco, CA, USA.
  • Hannah Kaiser
    Vir Biotechnology, San Francisco, CA, USA.
  • Martin Montiel-Ruiz
    Vir Biotechnology, San Francisco, CA, USA.
  • Julia Noack
    Vir Biotechnology, San Francisco, CA, USA.
  • Florian A. Lempp
    Vir Biotechnology, San Francisco, CA, USA.
  • Javier Janer
    Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
  • Rana Abdelnabi
    KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
  • Piet Maes
    KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
  • Paolo Ferrari
    Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Alessandro Ceschi
    Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Olivier Giannini
    Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Guilherme Dias de Melo
    Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
  • Lauriane Kergoat
    Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
  • Hervé Bourhy
    Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
  • Johan Neyts
    KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
  • Leah Soriaga
    Vir Biotechnology, San Francisco, CA, USA.
  • Lisa A. Purcell
    Vir Biotechnology, San Francisco, CA, USA.
  • Gyorgy Snell
    Vir Biotechnology, San Francisco, CA, USA.
  • Sean P.J. Whelan
    Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
  • Antonio Lanzavecchia
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Herbert W. Virgin
    Vir Biotechnology, San Francisco, CA, USA.
  • Luca Piccoli
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Helen Y. Chu
    Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
  • Matteo Samuele Pizzuto
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Davide Corti
    Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • David Veesler
    Department of Biochemistry, University of Washington, Seattle, WA, USA.

Description

<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant–neutralizing antibody that is a strong candidate for clinical development.</jats:p>

Journal

  • Science

    Science 378 (6620), 619-627, 2022-11-11

    American Association for the Advancement of Science (AAAS)

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top